“We have made the very difficult decision to discontinue some research projects to focus on programs where our innovation and investments may be best positioned to deliver high-impact breakthrough medicines and vaccines,” a Pfizer spokesperson told Becker’s.
The company noted that there may be opportunities for some employees to transition to new roles created within the company.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
